Research carried out at the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, has concluded that it would be a safe and cost-effective strategy to screen people with type 2 diabetes who have not yet developed diabetic retinopathy, for the disease once every two years instead of annually.
The research is supported by funding from the National Institute for Health Research Peninsula Collaboration for Leadership in Applied Health Research and Care (NIHR PenCLAHRC). It is published today (00:01hrs BST Monday 7th May 2012) on-line in Diabetes Care.
Diabetic retinopathy is a common complication of diabetes. It occurs when high blood sugar levels damage the cells in the retina and, if not treated, can lead to blindness. In all but some cases diabetic retinopathy has a typically slow rate of progression and can take years to develop.
The research team developed a model that simulated the progression of retinopathy in type 2 diabetes and related screening, in order to predict the rates of retinopathy-related sight loss. The model used data from the Royal Devon & Exeter NHS Foundation Trust in the South West of the UK and the research team generated comparative 15-year forecasts to assess the differences between current screening policies and those proposed by the findings of the study.
The study concluded that it is safe to screen type 2 diabetes patients who have not been diagnosed with retinopathy every two years rather than annually, because the research team found that the proportion of patients who develop retinopathy-related sight loss was no different between the two screening intervals.
Proposed savings for the Royal Devon & Exeter Hospital, for which 3,537 of the patients it screens for retinopathy fell into the remit of this study, would be a reduction in costs from £1.83m a year to £1.36m. The study predicts savings of around 25 per cent based on standard assumptions of screening costs.
According to Diabetes UK, some 2.8m people in the UK have diabetes and 10 per cent of them are diagnosed with retinopathy.
The UK's National Institute for Clinical Excellence introduced guidelines for annual screening, but admits that this frequency is arbitrary and has welcomed research to investigate appropriate intervals between screening appointments.
The study was led by Dr. Daniel Chalk, Associate Research Fellow in Applied Operational Research, Peninsula Collaboration for Health, Operational Research and Development (PenCHORD), PCMD. He said: "This is not the first study to investigate screening for diabetic retinopathy, but it is the first to focus on the group of type 2 diabetics who have not yet been diagnosed for the condition. Diabetic retinopathy typically develops at a very slow pace, and as a consequence we wanted to identify whether or not there was any merit in reducing the frequency of screening from annually to every two years."
He added: "We found that there was no perceivable difference in the effectiveness of screening annually or every two years for this particular patient cohort, which would suggest that it would be safe and cost-effective to increase the screening interval to two years. In order to support this, an effective recall system and campaign to impress upon patients the continuing importance of such screening would be beneficial – a lengthening of the screening interval in no way undermines the validity of the screening process itself."
Notes to Editors
The Peninsula Medical School is a joint entity of the University of Exeter, the University of Plymouth and the NHS in the South West of England, and a partner of the Combined Universities in Cornwall. The Peninsula Medical School has created for itself an excellent national and international reputation for groundbreaking research in the areas of diabetes and obesity, neurological disease, child development and ageing, clinical education, health and the environment and health technology assessment. The Peninsula Medical School is licensed under the Human Tissue Act to hold ethically acquired human tissue.
NIHR- PenCLAHRC aims to bring together local universities and their surrounding NHS organisations to test new treatments and new ways of working in specific clinical areas, to see if they are effective and appropriate for everyday use in the health service. Where potential improvements are identified, PenCLAHRC helps NHS staff to incorporate them into their everyday working practices, so that patients across the local community receive a better standard of healthcare.
The National Institute for Health Research provides the framework through which the research staff and research infrastructure of the NHS in England is positioned, maintained and managed as a national research facility. The National Institute for Health Research provides the NHS with the support and infrastructure it needs to conduct first-class research funded by the Government and its partners alongside high-quality patient care, education and training. Its aim is to support outstanding individuals (both leaders and collaborators), working in world class facilities (both NHS and university), conducting leading edge research focused on the needs of patients. http://www.nihr.ac.uk/
Andrew Gould | EurekAlert!
Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland
Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
22.03.2017 | Materials Sciences
22.03.2017 | Physics and Astronomy
22.03.2017 | Materials Sciences